MARKETS / NASDAQ / PDEX

NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

PRO DEX Inc. PDEX

16 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$77.5M

▲ 16.5% YoY

Net income

$13.7M

▲ 52.2% YoY

Free cash flow

$6.8M

In brief

What this company does

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. It also manufactures and sells rotary air motors to a wide range of industries, though these motors comprise a de minimis portion of its business. The majority of its revenue is derived from designing, developing and manufacturing surgical devices for the medical device industry. The company has only one operating segment as its business is currently operated. Its principal headquarters are located at 2361 McGaw Avenue, Irvine, California, and it also operates a facility in Tustin, California. At June 30, 2025 and 2024, the company had 181 and 148 employees, respectively, two of whom were part time, and all were working at one or both of its facilities in Irvine, California and Tustin, California.

Written from the business description in PRO DEX INC's annual report to the U.S. Securities and Exchange Commission, filed 4 September 2025. Every sentence was checked against that document before publication.

Growth

USD 77.5M

Revenue, FY2025 · full 16-year series below

Revenue $M Net income $M

FY2025 · Revenue 77.5 · Net income 13.7

Compound annual growth

Revenue

+18.9%

+15.3%

+15.0%

+8.1%

Net income

+24.5%

+17.2%

+32.5%

+11.6%

EPS, diluted

+28.3%

+21.3%

+35.3%

+11.5%

Returned to shareholders

+30.1%

−9.3%

+22.3%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +15.3% a year over five years — but profit grew faster: net income at +17.2%, earnings per share at +21.3%.

The share count fell from 0.00B to 0.00B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

0 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 16.8% · Net 0.0%

ROE

FY2025 · ROE 32.4%

Gross margin31.4%

Operating margin16.8%

Net margin0.0%

Return on assets0.0%

EBITDAUSD 14.4M

Each USD of equity produced 32 cents of profit this year.

Cash & shareholders

USD 3.4M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 6.8

Net buybacks $M Dividends $M

FY2025 · Dividends — · Net buybacks 3.4

Dividends paid—

Net buybacksUSD 3.4M

Share of profit24.9%

Consecutive raises—

USD 3.4M in buybacks — 25% of the year's profit went back to shareholders.

Total assetsUSD 74.5M

EquityUSD 47.6M

CashUSD 8.2M

Gross debtUSD 17.5M

Net debtUSD 9.3M

Current ratio4.10×

Net debt stands at 20% of equity.

The 16-year record

16 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue $B	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Operating income $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.0	−0.0	0.0
EBITDA $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.0	−0.0	0.0
Income tax $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	−0.0	−0.0	−0.0	−0.0	0.0
Net income $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.0	−0.0	0.0
Free cash flow $B	0.0	−0.0	·	·	−0.0	−0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.0	−0.0	0.0
EPS, diluted $	4.12	2.67	0.60	1.95	1.21	1.57	1.50	0.97	0.37	1.25	0.20	−0.09	−0.14	−0.54	−0.27	0.80
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
ROE %	32.4	26.6	6.8	24.8	19.6	30.7	33.9	24.2	10.5	45.0	9.5	−4.1	−5.7	−20.4	−8.8	25.6
Shares out B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 15 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivitySurgical & Medical Instruments & Apparatus

Listed onNASDAQ

Incorporated innot stated in the filings

Fiscal year endsJune 30

SEC categorysmaller reporting company

Data on record since2010